Home › Blog › Weight Loss › Mounjaro Side Effects UK

Mounjaro Side Effects UK 2026: The Complete Clinical Guide — Every Symptom, Every Management Strategy

Overview: Mounjaro Side Effects — What You Actually Need to Know

Mounjaro (tirzepatide) is the most effective weight loss injection currently available in the UK, with average weight loss of 22.5% of starting body weight at the 15mg dose. For most patients, the clinical benefits significantly outweigh the side effects. But side effects are real, they are common particularly during dose escalation, and knowing how to manage them is the difference between successful treatment and unnecessary discontinuation.

As a superintendent pharmacist with 25 years of clinical experience and hundreds of Mounjaro patients monitored through Slinic’s monthly check-ins, I have written this guide to give you the most clinically grounded, most practically useful side effects resource available in the UK. Not a list — a complete clinical management guide.

The headline statistics from SURMOUNT-1, the landmark Phase 3 trial that formed the basis of Mounjaro’s MHRA approval:

How Common Are Mounjaro Side Effects? The Full Data

The most important context for understanding Mounjaro side effects is this: the majority are gastrointestinal, the majority are mild to moderate, and the vast majority resolve without discontinuing treatment. The key driver of side effect severity is how carefully the dose escalation is managed — which is exactly why Slinic’s monthly check-in reviews every dose increase before approving it.

In SURMOUNT-1, the Phase 3 trial supporting MHRA approval of Mounjaro for weight management, the following were reported in the group taking the highest 15mg dose:

Data from SURMOUNT-1 (Jastreboff AM et al., NEJM 2022) and Mounjaro UK Summary of Product Characteristics. Percentages are approximate and rounded from published trial data.

Dose-Specific Side Effects: What Changes at Each Dose

A critical clinical insight from SURMOUNT-1 is that side effects are dose-dependent — meaning higher doses produce higher rates of gastrointestinal side effects. This is exactly why the gradual escalation protocol exists, and why Slinic’s policy of reviewing every dose increase at your monthly check-in before approving it is not just a formality.

Mounjaro Side Effects: Week-by-Week Timeline

Understanding when to expect side effects — and when they should resolve — is one of the most practically useful things this guide can give you. Here is what most patients experience across the first 16 weeks of treatment based on clinical trial data and Slinic’s patient monitoring experience.

Nausea: The Most Common Mounjaro Side Effect — Complete Management Guide

Nausea is experienced by approximately 20–32% of Mounjaro patients depending on dose, making it the most common side effect. It is most pronounced in the first days after a new dose, and the vast majority of patients find it significantly reduces within 1–2 weeks at each dose level. Here is the complete clinical management guide.

Why Mounjaro causes nausea

Tirzepatide activates GLP-1 receptors in both the gut and the brainstem — including the area postrema, the brain’s vomiting control centre. By slowing gastric emptying (food stays in the stomach longer), it produces the sensation of fullness that suppresses appetite. The same mechanism that creates fullness can also trigger nausea when the stomach empties slowly after eating.

When nausea is worst

• The first 2–7 days after each new dose — almost all patients experience a brief return of nausea with each escalation
• After eating large meals, high-fat foods, or very rich foods
• When eating too quickly
• When lying down shortly after eating
• After drinking alcohol, particularly in the first weeks of each dose

Evidence-based management strategies

• Eat smaller, more frequent meals — the most effective single intervention. Smaller portions mean less stomach distension, faster gastric emptying, and significantly less nausea. Think 4–5 small meals rather than 3 large ones.
• Avoid high-fat foods around injection day — fat slows gastric emptying further. Fried foods, creamy sauces, and fatty meats amplify nausea on Mounjaro. Light, easily digestible meals on injection day and the day after significantly reduce nausea severity.
• Stay upright after eating — do not lie down for at least 2 hours after eating. Gravity helps gastric emptying and significantly reduces nausea and reflux.
• Eat slowly and chew thoroughly — rapid eating fills the stomach faster and delays emptying, directly worsening nausea.
• Stay well hydrated — sipping water throughout the day rather than drinking large amounts at once. Dehydration worsens nausea.
• Avoid alcohol — particularly in the first weeks of each dose. Alcohol is a gastric irritant and significantly amplifies Mounjaro-related nausea.
• Time your injection — some patients find injecting in the evening means the peak nausea period (first 24–48 hours) occurs during sleep when it is less disruptive. Discuss with your Slinic clinician.
• Ginger — ginger tea, ginger biscuits, or ginger capsules have modest antiemetic evidence and are safe to use alongside Mounjaro. Worth trying before escalating to antiemetic medication.

Diarrhoea and Constipation: What to Do

Diarrhoea affects approximately 15–23% of Mounjaro patients depending on dose. Constipation affects approximately 11–17%. Both are a consequence of Mounjaro’s effect on gastrointestinal motility — GLP-1 receptor activation alters gut movement patterns, producing either speeded transit (diarrhoea) or slowed transit (constipation) depending on individual gut response.

Managing diarrhoea

• Stay hydrated — the priority with diarrhoea is maintaining fluid intake. Sip water, diluted fruit juice, and electrolyte drinks throughout the day. Diarrhoea-related dehydration can worsen kidney function and cause dizziness.
• Low-fibre foods temporarily — white rice, plain pasta, toast, and bananas (the BRAT diet principles) can help slow gut transit during acute episodes.
• Avoid high-fat, spicy, or very sweet foods — all of these accelerate gut motility and worsen diarrhoea on GLP-1 medications.
• Loperamide (Imodium) — safe to use for acute diarrhoea on Mounjaro for short periods. Discuss with your Slinic clinician before regular use.
• Probiotics — some evidence suggests that probiotics can reduce GI side effects from GLP-1 medications. Lactobacillus and Bifidobacterium strains are the most studied. Generally safe to take alongside Mounjaro.

Managing constipation

• Increase dietary fibre gradually — oats, vegetables, pulses, and whole grains support gut motility. Increase intake gradually to avoid bloating.
• Hydration is essential — inadequate fluid intake is the most common cause of constipation on Mounjaro. Aim for 2–2.5 litres of fluid per day.
• Physical activity — even light walking significantly improves gut motility. A 20-minute walk after meals can meaningfully reduce constipation.
• Osmotic laxatives — macrogol (e.g. Movicol, Laxido) is safe to use alongside Mounjaro and is the first-line recommendation for constipation that does not respond to dietary measures. Discuss dosing with your Slinic clinician.
• Avoid stimulant laxatives for regular use — senna and bisacodyl can cause dependence with regular use. Osmotic agents are preferred for ongoing management.

Vomiting: When to Be Concerned

Vomiting affects approximately 6–11% of Mounjaro patients. It is most common in the first days of a new dose and typically resolves within a week. For most patients, vomiting is an extension of the nausea pattern — the same triggers and management strategies apply. However, there are situations where vomiting on Mounjaro requires prompt clinical attention.

Managing vomiting

• Sip small amounts of clear fluid regularly — avoid gulping large amounts which can trigger further vomiting
• Eat very small amounts of bland food once vomiting has settled — do not try to eat a full meal
• Consider antiemetic medication: domperidone (Motilium) or metoclopramide can be prescribed by your Slinic clinician where appropriate
• If vomiting occurs within 4 hours of your weekly injection, contact Slinic before your next scheduled dose — dose timing may need adjustment

Fatigue and Headache

Fatigue affects approximately 8–11% of Mounjaro patients. It is most common in the first weeks of treatment and typically improves as the body adapts. The mechanism is not entirely understood but is likely related to a combination of reduced calorie intake, the metabolic changes associated with GLP-1 receptor activation, and the significant physiological adjustment required during dose escalation.

Managing fatigue on Mounjaro

• Adequate calorie intake — Mounjaro can suppress appetite so effectively that some patients eat far too little, particularly in the first weeks. Sustained fatigue may be a sign of insufficient nutrition. Ensure you are eating enough protein and total calories — discuss with your Slinic clinician at your monthly check-in.
• Protein prioritisation — adequate protein intake (aim for at least 1.2g per kilogram of body weight per day) supports energy levels and lean muscle preservation during weight loss.
• Sleep quality — weight loss itself can temporarily disrupt sleep patterns. Poor sleep amplifies fatigue. Address sleep hygiene if fatigue is persistent.
• Gradual activity increase — starting light physical activity often paradoxically improves energy levels, even when fatigue makes this feel counterintuitive.
• Hydration — mild dehydration is a common, overlooked cause of fatigue. Aim for 2+ litres of fluid per day.

Headaches

Headaches are reported by a smaller proportion of Mounjaro patients than the major GI side effects, but they are a recognised symptom, particularly in the first weeks of treatment. They are most commonly attributed to reduced fluid and food intake (dehydration and mild hypoglycaemia-adjacent states). Standard analgesics including paracetamol are safe to take alongside Mounjaro. Persistent or severe headaches warrant a conversation with your Slinic clinician.

Hair Loss (Telogen Effluvium): Why It Happens and What to Do

Hair loss is one of the most distressing side effects patients report on Mounjaro — but it is frequently misunderstood. Approximately 5–6% of patients on the highest Mounjaro doses report hair loss. Understanding the mechanism is essential to managing the anxiety around it.

What is telogen effluvium?

Hair grows in cycles — a growth phase (anagen), a transitional phase (catagen), and a resting phase (telogen) before shedding. Under normal circumstances, approximately 10–15% of hairs are in the telogen (resting) phase at any one time. When the body experiences significant physiological stress — including rapid weight loss, surgery, major illness, or significant dietary change — a larger proportion of hairs simultaneously enter the telogen phase. The result is increased shedding approximately 2–4 months after the triggering event.

Crucially: the hair loss associated with Mounjaro is almost certainly caused by the physiological stress of rapid weight loss, not by tirzepatide itself. The same pattern of hair loss is seen with bariatric surgery, very low calorie diets, and other forms of rapid weight loss — none of which involve Mounjaro. The medication is not damaging hair follicles; the body is responding to the metabolic stress of losing weight quickly.

What to expect

• Typically begins 2–4 months after starting treatment or after a significant dose increase
• Increased shedding when washing or brushing hair — not total or patchy hair loss
• Usually self-limiting — the vast majority of cases resolve within 3–6 months as the body adjusts
• Does not typically lead to visible thinning for most patients, though some notice reduced density

What helps

• Adequate protein intake — the single most important intervention. Protein deficiency is the nutritional factor most strongly associated with hair loss during weight loss. Aim for at least 1.2–1.6g protein per kilogram of target body weight per day.
• Iron levels — check serum ferritin at your next GP review. Low iron (even without frank anaemia) is a common contributing factor to hair shedding, particularly in women. Supplementation if levels are low.
• Zinc and biotin — some evidence supports supplementation. Generally safe alongside Mounjaro.
• Gentle hair care — avoid heat styling and aggressive brushing during periods of increased shedding.
• Do not stop Mounjaro — hair loss will typically resolve without stopping treatment. Stopping and restarting does not prevent telogen effluvium and will mean losing the significant clinical benefits of sustained treatment.

Mounjaro Face and Loose Skin: What Patients Need to Know

“Mounjaro face” is the colloquial term patients use to describe facial volume loss during significant weight loss on Mounjaro. It is not a drug side effect in the traditional pharmacological sense — it is an inevitable consequence of losing a significant proportion of body weight, which is now possible to an unprecedented degree on Mounjaro.

Why does it happen?

When the body loses fat, it does so systemically — not in a targeted way. Facial fat is often lost relatively early in the weight loss process, and its loss is more immediately visible because the face is what others see most. As facial fat volume reduces, the skin — which expanded to accommodate the larger volume — may appear looser, creating folds or sagging at the cheeks, jowls, and neck. Skin collagen density also decreases with age, making this more pronounced in older patients.

Loose skin more broadly

Loose skin in other areas — arms, abdomen, thighs — is a common concern for patients losing 20%+ of body weight on Mounjaro. The skin’s ability to contract after volume loss depends on age, genetics, the rate of weight loss, and the total amount of weight lost. Patients who lose weight more slowly, maintain good skin hydration, avoid smoking, and minimise UV exposure tend to have better skin contraction than those who lose weight very rapidly.

Management and expectations

• Adequate protein intake — collagen synthesis requires adequate protein and vitamin C. Prioritising protein throughout treatment supports skin structural integrity.
• Resistance exercise — building underlying muscle mass as fat is lost significantly improves the appearance of skin by filling the space previously occupied by fat with lean tissue.
• Skin hydration — topical moisturisation and adequate fluid intake support skin elasticity.
• Gradual weight loss where possible — staying at lower doses longer, where clinically appropriate, produces slower weight loss with potentially better skin contraction.
• For facial concerns — dermal fillers, skin booster treatments, and other aesthetic interventions can address volume loss. These are separate to your Mounjaro treatment. Slinic’s sister clinic HH Aesthetics offers aesthetic consultations for patients concerned about facial volume changes during weight loss treatment.

Muscle Cramps and Aches

Muscle cramps and aches are not listed as a common side effect in Mounjaro’s Summary of Product Characteristics, but they are a frequently reported patient experience — and there are clear physiological reasons why they occur.

Why do muscle cramps occur on Mounjaro?

• Electrolyte imbalances — reduced food intake can lead to lower intake of potassium, magnesium, and calcium — minerals that are essential for normal muscle function. Deficiencies in any of these can cause muscle cramps, spasms, and aches.
• Dehydration — Mounjaro suppresses appetite, and some patients also reduce their fluid intake. Dehydration concentrates electrolytes abnormally and directly triggers muscle cramps.
• Lean muscle loss — rapid weight loss without adequate protein and resistance exercise can cause muscle mass loss, making remaining muscle more susceptible to cramping.
• Medication interactions — some patients on diuretics, ACE inhibitors, or other medications that affect electrolytes may be more susceptible.

Managing muscle cramps on Mounjaro

• Ensure adequate hydration — 2–2.5 litres of fluid per day
• Include electrolyte-rich foods — bananas (potassium), nuts and seeds (magnesium), dairy or fortified alternatives (calcium)
• Consider an electrolyte supplement or sports drink if cramping is frequent
• Increase protein intake to support lean muscle preservation
• Start or maintain resistance exercise — even light weights or resistance bands 2–3 times per week
• Discuss with your Slinic clinician if cramping is severe — a blood test checking electrolyte levels may be appropriate

Injection Site Reactions

Injection site reactions — redness, swelling, itching, or bruising at the injection site — affect approximately 3–5% of Mounjaro patients. They are usually mild and temporary. Here is how to minimise them:

• Rotate injection sites — use a different location each week. Rotate between the abdomen (at least 2 inches from the navel), outer thighs, and upper arms. Never inject into the same spot twice consecutively.
• Allow room temperature before injecting — cold medication from the fridge can irritate tissue. Allow the pen to warm to room temperature for 30 minutes before injecting.
• Do not inject into areas of broken, irritated, or bruised skin
• Pinch the skin gently before injecting — this ensures subcutaneous delivery and reduces discomfort
• Apply gentle pressure after injection — do not rub the site, but gentle pressure for 10–15 seconds reduces bruising

Persistent or worsening injection site reactions — particularly hardened lumps under the skin (lipohypertrophy) — should be reported to your Slinic clinician. Avoiding affected sites and rotating correctly usually resolves this.

Serious Side Effects: What to Watch For

The following are rare but require immediate medical attention if they occur. Do not wait for your next monthly check-in — seek urgent assessment or contact emergency services where indicated.

Pancreatitis: The January 2026 MHRA Update

In January 2026, the MHRA issued an updated Drug Safety Update for GLP-1 receptor agonists including tirzepatide (Mounjaro), highlighting an updated assessment of the risk of acute pancreatitis. This update is important and is reflected in the current Mounjaro patient information leaflet.

What the MHRA updated guidance says

• Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists including Mounjaro
• The absolute risk is low — fewer than 0.2% of patients in clinical trials experienced pancreatitis
• Patients should be counselled to recognise the symptoms: severe, persistent pain in the upper abdomen, often radiating to the back, usually accompanied by nausea or vomiting
• Mounjaro should be stopped immediately if pancreatitis is suspected and not restarted if confirmed
• Patients with a history of pancreatitis should discuss this carefully with their prescriber before starting Mounjaro — it may not be appropriate

At Slinic, we screen for pancreatitis history at every initial consultation, and we discuss the symptoms to watch for with all new patients. If you have any concern about abdominal pain while taking Mounjaro, contact us immediately — do not wait.

Contraceptive Pill Interaction: What You Must Know

The MHRA Drug Safety Update (January 2025) confirmed that Mounjaro may reduce the effectiveness of oral contraceptive pills. This is one of the most clinically important drug interactions for Mounjaro patients of reproductive age, and it is covered in detail in our Mounjaro and contraception clinical guide.

Why does this happen?

Mounjaro slows gastric emptying — food and medications move through the stomach more slowly. The combined oral contraceptive pill relies on consistent absorption timing through the gut. When gastric emptying is delayed by tirzepatide, the pill may not be absorbed at the expected rate or in the expected amount, potentially reducing its contraceptive effectiveness.

What to do

• Use an additional barrier method (condoms) for at least four weeks after starting Mounjaro and for four weeks after each dose increase
• Alternatively, discuss switching to a non-oral contraceptive (patch, IUD, implant, injectable) with your Slinic clinician or GP
• This advice applies specifically to Mounjaro — the interaction is related to tirzepatide’s specific gastric emptying effect and may be less pronounced with injectable GLP-1 medications

Mounjaro and Thyroid Medication

Patients taking levothyroxine or other thyroid medications need to be aware of two separate interactions with Mounjaro. This is covered in full in our Mounjaro and thyroid medication dosage guide.

1. Absorption timing interaction

Levothyroxine is typically taken on an empty stomach, first thing in the morning, and must not be taken within 30 minutes of food or other medications. Mounjaro’s effect on gastric emptying can alter levothyroxine absorption timing and bioavailability. Patients taking levothyroxine should discuss the timing protocol with their Slinic clinician at consultation.

2. Thyroid function changes with weight loss

Significant weight loss — of the magnitude commonly achieved on Mounjaro — can improve thyroid function in some patients with hypothyroidism, potentially meaning that their levothyroxine dose needs to be reduced. Regular thyroid function monitoring is advisable for all patients on levothyroxine who are losing significant weight on any treatment.

Should You Stop Mounjaro If You Get Side Effects?

This is one of the most important questions in this guide. The answer in most cases is: no — speak to your Slinic clinician first.

The vast majority of Mounjaro side effects are manageable with the strategies in this guide, with dose adjustment, or with short-term antiemetic or antidiarrhoeal medication. Patients who stop Mounjaro abruptly due to side effects lose all the clinical benefit accumulated to that point, and restarting from scratch at 2.5mg means going through the escalation process again.

Options your Slinic clinician can discuss before stopping include:

• Dose reduction — reverting to the previous, better-tolerated dose
• Slower escalation — extending the time at each dose beyond the standard 4-week interval
• Antiemetic medication — domperidone or metoclopramide prescribed short-term
• Dietary modification review — often the most effective and underutilised intervention
• Switching medications — where Mounjaro is genuinely not tolerated, switching to Wegovy (semaglutide) with a fresh dose escalation may produce better tolerability for some patients. See our switching guide.

Frequently Asked Questions

Mounjaro Side Effects vs Wegovy: Which Is Better Tolerated?

A question many patients ask before starting is whether Mounjaro or Wegovy has a better side effect profile. The honest answer is that they are broadly similar — both activate GLP-1 receptors and produce the same class of gastrointestinal effects. The differences are subtle but clinically meaningful for some patients. For a full clinical comparison see our Mounjaro vs Wegovy guide.

The most notable difference is dysaesthesia — tingling or altered skin sensations — which is reported at 22.9% of patients on the Wegovy 7.2mg dose but is not a recognised side effect of Mounjaro at standard doses. For patients for whom this would be particularly problematic, Mounjaro may be the preferable option. Conversely, nausea and vomiting rates are modestly lower with Mounjaro than with Wegovy 2.4mg — a small but relevant difference for some patients.

If you experience significant side effects on Mounjaro and want to consider switching to Wegovy, see our complete Mounjaro to Wegovy switching guide.

Managing Side Effects Long-Term: What Changes at Maintenance

Most discussions of Mounjaro side effects focus on the escalation phase — the first 4–6 months of treatment. But what happens at maintenance? What should patients expect when they reach their target dose and stay there for 12 months or longer?

What typically improves at maintenance

• Gastrointestinal side effects — the vast majority of patients who experience nausea, diarrhoea, or constipation during escalation find these significantly reduce or resolve entirely at an established maintenance dose. The body’s adaptation to tirzepatide at a steady dose is robust.
• Fatigue — typically resolves as the body adapts and as improved nutrition and weight loss improve overall energy levels.
• Food sensitivity — many patients find they can gradually reintroduce foods that triggered nausea during escalation, once at a stable maintenance dose.

What may persist or emerge at maintenance

• Reduced appetite — this is the intended therapeutic effect and persists throughout treatment. Some patients on long-term maintenance need to be consciously reminded to eat adequate nutrition, particularly protein.
• Lean muscle considerations — with ongoing weight loss at maintenance, continued attention to protein intake and resistance exercise remains important.
• Injection site rotation — injection site reactions can emerge if rotation discipline lapses. Maintaining the rotation protocol throughout maintenance prevents lipohypertrophy.
• Reflux — some patients notice mild gastroesophageal reflux persisting at maintenance. Eating smaller meals, remaining upright after eating, and avoiding trigger foods manages this effectively. Discuss with your Slinic clinician if persistent.

How to Report Mounjaro Side Effects

If you experience any side effect from Mounjaro — expected or unexpected — there are two routes for reporting:

Report to Slinic

Your first port of call for any side effect concern should be your Slinic clinical team. Contact us between monthly appointments if you have any concern — do not wait. Contact Slinic →

Report to the MHRA Yellow Card scheme

All patients taking prescription medicines in the UK can report suspected side effects directly to the MHRA through the Yellow Card scheme — regardless of whether they believe the side effect is definitely caused by the medication. These reports are how the MHRA monitors post-market safety of all medicines including Mounjaro. You can report at yellowcard.mhra.gov.uk or through the Yellow Card app. Your report contributes to the UK’s medicine safety database.

Clinical References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387(3):205-216.
2. Garvey WT, et al. Tirzepatide for obesity in type 2 diabetes (SURMOUNT-2). The Lancet. 2023;402(10402):613-626.
3. MHRA Drug Safety Update: Tirzepatide (Mounjaro) and GLP-1 receptor agonists — pancreatitis and oral contraceptive interaction. January 2025.
4. Electronic Medicines Compendium. Mounjaro KwikPen Summary of Product Characteristics. 2026.
5. Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity. NEJM. 2025;393(1):26-36.
6. NICE TA1026 — Tirzepatide for managing overweight and obesity.
7. GPhC. Guidance for registered pharmacies providing services at a distance. Updated February 2025. pharmacyregulation.org

Related Guides & Treatment Pages